Formulation and In Vitro Evaluation of Bilayer Tablets of Nebivolol Hydrochloride and Nateglinide for the Treatment of Diabetes and Hypertension

Table 13

In vitro drug release data of Nebivolol immediate release tablets (NBL1–NBL9).

Time	NBL-1	NBL-2	NBL-3	NBL-4	NBL-5	NBL-6	NBL-7	NBL-8	NBL-9
0	0	0	0	0	0	0	0	0	0
5	11 ± 3.12	16 ± 3.26	14 ± 3.11	19 ± 3.80	16 ± 3.57	19 ± 3.85	19 ± 24	25 ± 3.96	27 ± 3.68
10	21 ± 3.45	28 ± 3.40	25 ± 4.25	28 ± 3.54	29 ± 4.20	32 ± 3.15	31 ± 3.20	43 ± 3.56	41 ± 3.24
15	35 ± 3.08	36 ± 4.05	34 ± 4.50	38 ± 3.69	42 ± 4.22	46 ± 4.12	48 ± 4.01	50 ± 3.94	58 ± 3.80
20	49 ± 4.15	50 ± 4.91	47 ± 3.75	52 ± 4.52	58 ± 3.75	59 ± 3.46	60 ± 4.23	66 ± 4.25	73 ± 4.31
25	55 ± 3.89	61 ± 3.89	53 ± 3.90	59 ± 3.96	64 ± 3.58	66 ± 4.29	70 ± 3.99	80 ± 3.98	88 ± 3.78
30	64 ± 4.52	69 ± 3.68	65 ± 4.82	68 ± 4.95	74 ± 4.52	80 ± 4.42	84 ± 4.58	96 ± 3.80	97 ± 3.94